Sponsor:
QED Therapeutics, a BridgeBio company
Code:
NCT07169279
Conditions
Achondroplasia
Eligibility Criteria
Sex: All
Age: 0 - 2
Healthy Volunteers: Not accepted
Interventions
Infigratinib is provided as a single dose of minitablets for oral administration
Infigratinib is provided as sprinkle capsules for daily oral administration
Infigratinib or placebo comparator is provided as sprinkle capsules for daily oral administration
Infigratinib is provided as sprinkle capsules for daily oral administration
Study Details
Eligibility Criteria
Study Design
Interventions and Outcome Measures
Central Contacts and Locations
More Information
Trial information was received from ClinicalTrials.gov and was last updated on 2026-02-11. This information was provided to ClinicalTrials.gov by QED Therapeutics, a BridgeBio company on 2025-12-15.